Physician profile
Raghav Gupta
NPI 1659668804
$9,792.85
in general payments reported to CMS, 2019-2025
37 companies · $1,859 in 2025
The $1,859 reported for 2025 was more than what 75% of Pulmonary Disease providers received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,416 · 2020: $821 · 2021: $989 · 2022: $1,025 · 2023: $2,629 · 2024: $1,054 · 2025: $1,859.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,238 · Travel and Lodging: $1,246 · Education: $57.61.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,237.95 |
| Travel and Lodging | $1,246.24 |
| Education | $57.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $1,541.20 | 2019-2025 | Trelegy Ellipta, Arexvy, Nucala |
| Astrazeneca Pharmaceuticals LP | $1,512.04 | 2019-2025 | Fasenra, Breztri, Airsupra |
| Ethicon INC. | $1,503.12 | 2022-2025 | Monarch Platform |
| Boehringer Ingelheim Pharmaceuticals, INC. | $975.77 | 2019-2025 | Ofev, Spiriva Respimat, Jascayd |
| Mylan Specialty L.P. | $576.51 | 2019-2024 | Yupelri |
| Insmed, INC. | $379.20 | 2020-2025 | Arikayce, Brinsupri |
| Sunovion Pharmaceuticals INC. | $365.93 | 2019-2021 | |
| Grifols USA, LLC | $313.92 | 2019-2025 | Prolastin-C Liquid |
| Blue Earth Diagnostics | $292.60 | 2025 | Posluma |
| Genzyme Corporation | $251.67 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $223.93 | 2019-2025 | Dupixent |
| Amgen INC. | $218.85 | 2020-2025 | Tezspire |
| Electromed, INC. | $198.82 | 2019-2025 | Smartvest |
| Viatris Specialty LLC | $163.29 | 2025 | Yupelri |
| Actelion Pharmaceuticals US, INC. | $157.96 | 2019-2024 | Opsumit, Uptravi |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $154.78 | 2019-2020 | |
| Travere Therapeutics, INC. | $124.99 | 2023 | |
| Teva Pharmaceuticals USA, INC. | $110.05 | 2020-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $100.45 | 2021-2023 | Glassia |
| Csl Behring | $99.37 | 2021-2025 | Kcentra, Haegarda |
| United Therapeutics Corporation | $93.78 | 2025 | Tyvaso |
| Merck Sharp & Dohme LLC | $79.07 | 2019-2025 | Keytruda, Capvaxive |
| Pulmonx Corporation | $57.08 | 2019-2024 | Pulmonx Chartis Tablet Console, Chartis Catheter, Zephyr Endobronchial Valve |
| Genentech USA, INC. | $39.00 | 2019-2021 | |
| E.R. Squibb & Sons, L.L.C. | $38.60 | 2019-2021 | |
| Coloplast Corp | $30.59 | 2025 | |
| Pfizer INC. | $28.40 | 2021-2023 | |
| Astellas Pharma US INC | $20.48 | 2019 | |
| Shionogi INC | $19.67 | 2023 | Fetroja |
| Chiesi USA, INC. | $18.68 | 2020 | |
| Monaghan Medical Corporation | $17.87 | 2023 | Aeroeclipse |
| Advanced Respiratory, INC | $16.89 | 2021 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $16.00 | 2023 | Lifevest |
| Ambu INC. | $14.68 | 2023 | |
| Abbvie INC. | $14.14 | 2021 | |
| Janssen Pharmaceuticals, INC | $12.45 | 2019 | |
| Circassia INC. | $11.02 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Raghav Gupta listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.